Ping Jiang

Dr. Ping Jiang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2023 in Medicine
Verified
Journal Article
Open access
JYJiali Mm Yang
Jiali Mm Yang
JWJiaojiao Bs Wu
Jiaojiao Bs Wu
THTingliang Han
Tingliang Han
HLHua Mm Lu
Hua Mm Lu
FLFangcun Li
Fangcun Li
ZHZhaomeng Hou
Zhaomeng Hou
The objective of this study is to utilize bibliometric and visual analysis techniques to identify hotspots and frontiers of research in myasthenia gravis (MG) and provide valuable references for future research. The Web of Science Core Collection (WoSCC) database was used to retrieve literature data related to MG research, which was then analyzed using VOSviewer 1.6.18, CiteSpace 6.1.R3, and the Online Platform for Bibliometric Analysis. The analysis revealed 6734 publications distributed across 1612 journals and contributed by as many as 24,024 authors affiliated with 4708 institutions across 107 countries/regions. The number of annual publications and citations for MG research has steadily increased over the past 2 decades, with the last 2 years alone witnessing a remarkable increase in annual publications and citations to over 600 and 17,000, respectively. In terms of productivity, the United States emerged as the top producing country, while the University of Oxford ranked first in terms of research institutions. Vincent A was identified as the top contributor in terms of publications and citations. Muscle & Nerve and Neurology ranked first in publications and citations respectively, with clinical neurology and neurosciences among the main subject categories explored. The study also identified pathogenesis, eculizumab, thymic epithelial cells, immune checkpoint inhibitors, thymectomy, MuSK antibodies, risk, diagnosis, and management as the current hot research topics in MG, while burst keywords like quality of life, immune-related adverse events (irAEs), rituximab, safety, nivolumab, cancer, and classification indicated the frontiers of MG research. This study effectively identifies the hotspots and frontiers of MG research, and offers valuable references for researchers interested in this area.

25 May 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
PJPing Jiang
Ping Jiang
KWKai Wei
Kai Wei
JZJianan Zhao
Jianan Zhao
YJYehua Jin
Yehua Jin
CCcen chang
cen chang
DHDongyi He
Dongyi He
Rheumatoid arthritis (RA) is a chronic, systemic, abnormal inflammatory immune response. It is characterized by the involvement of the synovium and multiple organs and the destruction of joints and articular cartilage. Over the past 30 years, several promising novel compounds and antibodies have been developed for the treatment of RA. The introduction of new drugs and precision medicine for all forms of RA raises several issues related to access to novel treatments by patients, optimal regimen selection, cost-effectiveness, prognosis monitoring and outcome surveillance, particularly with regarding to the development of low drug response rates, drug resistance and adverse side effects. Tremendous attention has been given to the identification of optimized drug combinations for the treatment of RA, particularly in early high-risk vulnerable and early individuals. Addressing these issues requires novel therapeutic approaches with new mechanisms and the establishment of accurate guidelines for drug selection, drug recombination, and non-chemical therapeutic efforts. In this study, we reviewed the most exciting recently established or ongoing novel drugs and methods according to the clinical trial database maintained by the United States National Library of Medicine and discussed the trends in RA drug development and challenges in the treatment, providing a reference significant for the accurate treatment of RA and the research direction in the future.

30 January 2026 in Medicine
Verified
Journal Article
Open access
PJPing Jiang
Ping Jiang
YJYouji Jia
Youji Jia
JZJuhua Zhang
Juhua Zhang
ZWZhi Wang
Zhi Wang
HMHonghong Ma
Honghong Ma
XXXiaobing Xi
Xiaobing Xi
Rheumatoid arthritis (RA) is a complex autoimmune disease. Recently, cell senescence has been identified as a key factor in its pathogenesis. This study integrated multi-omics summary data and applied Mendelian randomization (MR) and co-localization analysis to systematically evaluate the causal relationships between cell senescence-related genes and RA. We collected summary data on blood methylation quantitative trait loci (mQTL), expression quantitative trait loci, and protein quantitative trait loci. The FinnGen database was the primary discovery dataset, validated by the UK Biobank and GWAS Catalog. We used the summary-data-based MR method to assess causal associations between the molecular traits of cell senescence-related genes and RA. Co-localization analysis was then performed to confirm shared genetic variants. After integrating multi-omics data on cell senescence-related mQTL and expression quantitative trait loci, we identified 5 key cell senescence-related genes potentially associated with RA: BCL2L1 , DNMT3B , ERRFI1 , NEK4 , and RAF1 . These genes demonstrated significant causal associations across multiple analyses. The mQTL signals based on summary-data-based MR analysis show that the genetically regulated methylation variations at the cg12873919 (odds ratio [OR] = 0.91, 95% CI [0.84–0.99]) and cg13989999 (OR = 0.90, 95% CI [0.82–1.00]) sites of the BCL2L1 gene are negatively associated with RA risk and may mediate disease risk by upregulating gene expression (OR = 0.82, 95% CI [0.76–0.88] and OR = 0.78, 95% CI [0.71–0.87]). Conversely, the mQTL effect size at the cg26432171 site of the RAF1 (OR = 1.17, 95% CI [1.02–1.33]) is positively associated with RA risk and is consistent with the upregulation of gene expression (OR = 1.83, 95% CI [1.49–2.25]), thereby enhancing RA susceptibility. Moreover, several sites in the DNMT3B gene (e.g., cg09149842) exhibited negative correlations with RA risk, suggesting that DNMT3B may play a critical role in RA pathogenesis by affecting gene expression. Methylation sites in ERRFI1 (cg13808198, cg22678073) and NEK4 (cg09524078) were also associated with RA risk, supporting their potential regulatory roles in RA. Co-localization analysis further validated the association between methylation sites and RA, particularly for BCL2L1 , RAF1 , DNMT3B , ERRFI1 , and NEK4 , where we identified shared causal signals with RA (posterior probability of H4 > 0.5). This study systematically evaluated the causal relationships between cell senescence-related genes and RA risk. These findings provide new insights into RA pathogenesis and reinforce the clinical value of these genes as potential therapeutic targets.